Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

2019 update to Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Gut microbiota profile and selected plasma metabolites in type 1 diabetes without and with stratification by albuminuria

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Circulating metabolites in relation to presence and development of diabetic retinopathy in individuals with type 1 diabetes

    Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskningpeer review

  3. Integrated analysis of clinical and multi-dimension omics data from 100 newly diagnosed type 1 diabetes subjects from the INNODIA study

    Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskningpeer review

  4. Major decreases in the lipidome following liraglutide treatment

    Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskningpeer review

  1. Gut microbiota profile and selected plasma metabolites in type 1 diabetes without and with stratification by albuminuria

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. A Targeted Multiomics Approach to Identify Biomarkers Associated with Rapid eGFR Decline in Type 1 Diabetes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • John B Buse
  • Deborah J Wexler
  • Apostolos Tsapas
  • Peter Rossing
  • Geltrude Mingrone
  • Chantal Mathieu
  • David A D'Alessio
  • Melanie J Davies
Vis graf over relationer

The American Diabetes Association and the European Association for the Study of Diabetes have briefly updated their 2018 recommendations on management of hyperglycaemia, based on important research findings from large cardiovascular outcomes trials published in 2019. Important changes include: (1) the decision to treat high-risk individuals with a glucagon-like-peptide 1 (GLP-1) receptor agonist or sodium-glucose cotransporter 2 (SGLT2) inhibitor to reduce major adverse cardiovascular events (MACE), hospitalisation for heart failure (hHF), cardiovascular death or chronic kidney disease (CKD) progression should be considered independently of baseline HbA1c or individualised HbA1c target; (2) GLP-1 receptor agonists can also be considered in patients with type 2 diabetes without established cardiovascular disease (CVD) but with the presence of specific indicators of high risk; and (3) SGLT2 inhibitors are recommended in patients with type 2 diabetes and heart failure, particularly those with heart failure with reduced ejection fraction, to reduce hHF, MACE and CVD death, as well as in patients with type 2 diabetes with CKD (eGFR 30 to ≤60 ml min-1 [1.73 m]-2 or urinary albumin-to-creatinine ratio >30 mg/g, particularly >300 mg/g) to prevent the progression of CKD, hHF, MACE and cardiovascular death.

OriginalsprogEngelsk
TidsskriftDiabetologia
Vol/bind63
Udgave nummer2
Sider (fra-til)221-228
Antal sider8
ISSN0012-186X
DOI
StatusUdgivet - feb. 2020

ID: 58665478